Reporting Manager
Southpoint Master Fund, LP
Symbol
FENC
Shares outstanding
34,309,263 shares
Disclosed Ownership
2,744,741 shares
Ownership
8%
Form type
SCHEDULE 13G/A
Filing time
14 Jan 2026, 17:00:03 UTC
Date of event
31 Dec 2025

Quoteable Key Fact

"Southpoint Capital Advisors LP disclosed 8% ownership in Fennec Pharmaceuticals Inc. Common Shares, no par value (FENC) on 31 Dec 2025."

Quick Takeaways

  • Southpoint Capital Advisors LP filed SCHEDULE 13G/A for Fennec Pharmaceuticals Inc. Common Shares, no par value (FENC).
  • Disclosed ownership: 8%.
  • Date of event: 31 Dec 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Jan 2026, 17:00.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Southpoint Master Fund, LP 8% 2,744,741 0 2,744,741 /s/ John S. Clark II By Southpoint GP, LP, its General Partner, by Southpoint GP LLC, its General Partner, by John S. Clark II, Managing Member
Southpoint Capital Advisors LP 8% 2,744,741 0 2,744,741 /s/ John S. Clark II By Southpoint Capital Advisors LLC, its General Partner, by John S. Clark II, Managing Member
Southpoint Capital Advisors LLC 8% 2,744,741 0 2,744,741 /s/ John S. Clark II John S. Clark II, Managing Member
Southpoint GP, LP 8% 2,744,741 0 2,744,741 /s/ John S. Clark II John S. Clark II, Managing Member
Southpoint GP, LLC 8% 2,744,741 0 2,744,741 /s/ John S. Clark II John S. Clark II, Managing Member
John S. Clark II 8% 2,744,741 0 2,744,741 /s/ John S. Clark II John S. Clark II, individually
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .